Our capsid Virus-Like Particle display technology enables the development of best-in-class safe and efficacious vaccines to treat and prevent specific cancers, infectious diseases and immunological disorders.
Our lead candidate, ABNCoV2 COVID-19 vaccine, has met its primary objective in Phase 3, demonstrating non-inferiority to the Comirnaty® mRNA-vaccine. Additionally, safety data from 4,205 individuals followed up for 2 months post vaccination showed ABNCoV2 to be well-tolerated with no serious adverse events being reported.
To date, ABNCoV2 has demonstrated best-in-class 12 month durable antibody response in PhII.
AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, owned by the inventors of the novel proprietary and ground-breaking capsid Virus-Like Particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.